Literature DB >> 9022082

Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice.

S Funakoshi1, D D Taub, M R Anver, A Raziuddin, O Asai, V Reddy, H Rager, W C Fanslow, D L Longo, W J Murphy.   

Abstract

CD40 is a molecule present on multiple cell types including B lymphocyte lineage cells. CD40 has been shown to play an important role in B cell differentiation and activation in vitro, although little is known concerning the effects of CD40 stimulation in vivo. We therefore examined the effects of CD40 stimulation in mice using a syngeneic bone marrow transplantation (BMT) model in an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution. After the BMT, mice were treated with or without 2-6 microg of a soluble recombinant murine CD40 ligand (srmCD40L) given intraperitoneally twice a week. A significant increase in B cell progenitors (B220+/ surface IgM-) was observed in the bone marrow of mice receiving the srmCD40L. The treated recipients also demonstrated improved B-cell function with increases in total serum immunoglobulin and increased splenic mitogen responsiveness to LPS being noted. Additionally, srmCD40L treatment promoted secondary lymphoid organ repopulation, accelerating germinal center formation in the lymph nodes. Total B cell numbers in the periphery were not significantly affected even with continuous srmCD40L administration. Lymphocytes obtained from mice treated with the ligand also had increases in T cell mitogen and anti-CD3 mAb responsiveness and acquired the capability to produce IL-4. Surprisingly, treatment with srmCD40L also produced hematopoietic effects in mice, resulting in an increase of BM and splenic hematopoietic progenitor cells in the mice after BMT. Treatment with srmCD40L significantly increased granulocyte and platelet recovery in the peripheral blood. Incubation of BMC with srmCD40L in vitro also resulted in increased progenitor proliferation, demonstrating that the hematopoietic effects of the ligand may be direct. Thus, stimulation of CD40 by its ligand may be beneficial in accelerating both immune and hematopoietic recovery in the setting of bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9022082      PMCID: PMC507822          DOI: 10.1172/JCI119183

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Cross-linking CD40 on human B cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus.

Authors:  A W Larson; T W LeBien
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

Review 2.  CD40L: a multi-functional ligand.

Authors:  R J Armitage; C R Maliszewski; M R Alderson; K H Grabstein; M K Spriggs; W C Fanslow
Journal:  Semin Immunol       Date:  1993-12       Impact factor: 11.130

Review 3.  Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery.

Authors:  R Sackstein
Journal:  Semin Oncol       Date:  1993-10       Impact factor: 4.929

Review 4.  Immune recovery after bone marrow transplantation.

Authors:  L G Lum
Journal:  Hematol Oncol Clin North Am       Date:  1990-06       Impact factor: 3.722

5.  Activated CD4+ T cells induce CD40-dependent proliferation of human B cell precursors.

Authors:  N Renard; V Duvert; D Blanchard; J Banchereau; S Saeland
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  S J Brandt; W P Peters; S K Atwater; J Kurtzberg; M J Borowitz; R B Jones; E J Shpall; R C Bast; C J Gilbert; D H Oette
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

7.  Inhibition of human B-cell lymphoma growth by CD40 stimulation.

Authors:  S Funakoshi; D L Longo; M Beckwith; D K Conley; G Tsarfaty; I Tsarfaty; R J Armitage; W C Fanslow; M K Spriggs; W J Murphy
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

8.  Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease.

Authors:  F H Durie; A Aruffo; J Ledbetter; K M Crassi; W R Green; L D Fast; R J Noelle
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.

Authors:  I Stamenkovic; E A Clark; B Seed
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

10.  In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.

Authors:  A J Van den Eertwegh; R J Noelle; M Roy; D M Shepherd; A Aruffo; J A Ledbetter; W J Boersma; E Claassen
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  5 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity.

Authors:  Fan-ching Lin; Yue Peng; Leslie A Jones; Paulo H Verardi; Tilahun D Yilma
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

3.  CD154-CD40 interactions in the control of murine B cell hematopoiesis.

Authors:  Jennifer Carlring; Hala M Altaher; Susan Clark; Xi Chen; Sarah L Latimer; Tracey Jenner; Anne-Marie Buckle; Andrew W Heath
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

Review 4.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

5.  New frontiers for platelet CD154.

Authors:  Antoine Dewitte; Annabelle Tanga; Julien Villeneuve; Sébastien Lepreux; Alexandre Ouattara; Alexis Desmoulière; Christian Combe; Jean Ripoche
Journal:  Exp Hematol Oncol       Date:  2015-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.